Keystone Nano, Inc.

KEYSTONE NANO ANNOUNCES THE US FDA HAS AWARDED ORPHAN DRUG DESIGNATION FOR USE OF CERAMIDE FOR THE TREATMENT OF PANCREATIC CANCER

Cancer Solutions | State College | Keystone Nano, Inc. | News & Resources At Keystone Nano, we are solving big problems with nano solutions.  We are testing nanoscale therapies in cancer clinics around the United States.

The Promise of Nanomedicine

https://www.laboratoryequipment.com/article/2017/11/promise-nanomedicine

The Promise of Nanomedicine

The use of nanoparticulates to treat breast cancer -

The use of nanoparticulates to treat breast cancer. - PubMed - NCBI Nanomedicine (Lond). 2017 Oct;12(19):2367-2388. doi: 10.2217/nnm-2017-0202. Epub 2017 Sep 4.

Investigational cancer compound receives FDA approval to begin human trials: http://bit.ly/2uDyvQG

Investigational cancer compound receives FDA approval to begin human trials | Penn State University An investigational compound developed by Penn State researchers that targets and destroys cancer cells while leaving healthy cells unharmed has been approved for phase one clinical human trials by the U.S. Food and Drug Administration (FDA).

Keystone Nano Announces Progress On RNA Delivery

Keystone Nano Announces Progress On RNA Delivery STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical...